Eplerenone, a selective aldosterone receptor antagonist, has been used in clinical studies to reduce morbidity and mortality in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure (Pitt et al., 2023). Here, NR3C2 is linked to heart failure.